指南与共识重症综合管理与镇静镇痛心脑血管急症

2022年更新:兽医重症监护中抗血栓与溶栓药物合理使用共识(CURATIVE)第1部分——定义风险人群

2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 1- Defining populations at risk.
指南 / 共识 · J Vet Emerg Crit Care (San Antonio) · 2022-05-02
一句话结论CURATIVE 2022更新将心丝虫病和蛋白丢失性肠病定义为血栓高风险,肝病犬及患免疫介导性溶血性贫血、蛋白丢失性肾病、脓毒症或肾上腺皮质功能亢进的猫为低风险。

该共识采用人群-暴露-比较-结局格式,对多种疾病和干预措施与血栓的关联进行系统评价,并通过Delphi调查达成最终推荐。本次评估的疾病包括心丝虫病(犬和猫)、免疫介导性溶血性贫血(猫)、蛋白丢失性肾病(猫)、蛋白丢失性肠病(犬和猫)、脓毒症(猫)、肾上腺皮质功能亢进(猫)、肝病(犬)、先天性门体分流(犬和猫);干预措施包括静脉导管、动脉导管、血管通路装置、体外循环回路和经静脉起搏器(犬和猫)。结果为心丝虫病或蛋白丢失性肠病定义为血栓高风险;肝病犬及患免疫介导性溶血性贫血、蛋白丢失性肾病、脓毒症或肾上腺皮质功能亢进的猫定义为低风险。这些关联为管理推荐提供了依据,并指出了未来研究的知识空白。

要点

  • 心丝虫病(犬和猫)或蛋白丢失性肠病(犬和猫)被定义为血栓高风险。
  • 肝病犬被定义为血栓低风险。
  • 患免疫介导性溶血性贫血、蛋白丢失性肾病、脓毒症或肾上腺皮质功能亢进的猫被定义为血栓低风险。
  • 评估的干预措施包括静脉导管、动脉导管、血管通路装置、体外循环回路和经静脉起搏器(犬和猫)。
  • 共识指出存在多个知识空白,代表未来研究机会。

适用人群与场景

  • 评估的疾病人群:心丝虫病(犬和猫)、免疫介导性溶血性贫血(猫)、蛋白丢失性肾病(猫)、蛋白丢失性肠病(犬和猫)、脓毒症(猫)、肾上腺皮质功能亢进(猫)、肝病(犬)、先天性门体分流(犬和猫)。
  • 评估的干预人群:静脉导管(犬和猫)、动脉导管(犬和猫)、血管通路装置(犬和猫)、体外循环回路(犬和猫)、经静脉起搏器(犬和猫)。

诊断标准与关键阈值

  • 血栓高风险定义:心丝虫病或蛋白丢失性肠病。
  • 血栓低风险定义:肝病犬;患免疫介导性溶血性贫血、蛋白丢失性肾病、脓毒症或肾上腺皮质功能亢进的猫。

研究设计与关键结果

  • 本共识采用人群暴露比较结局格式,由工作表作者进行综合检索、总结证据并创建指南推荐,经领域主席审阅后通过Delphi调查达成最终共识。
  • 本次迭代评估的疾病包括心丝虫病(犬和猫)、免疫介导性溶血性贫血(猫)、蛋白丢失性肾病(猫)、蛋白丢失性肠病(犬和猫)、脓毒症(猫)、肾上腺皮质功能亢进(猫)、肝病(犬)、先天性门体分流(犬和猫)。
  • 本次迭代评估的干预措施包括静脉导管、动脉导管、血管通路装置、体外循环回路和经静脉起搏器(犬和猫)。
  • 血栓高风险定义为心丝虫病或蛋白丢失性肠病;低风险定义为肝病犬及患免疫介导性溶血性贫血、蛋白丢失性肾病、脓毒症或肾上腺皮质功能亢进的猫。

证据类型、等级与局限

  • 证据类型:指南/共识。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,各种疾病和干预措施与血栓的关联已概述,为管理推荐提供了依据。
  • 作者指出,已识别出多个知识空白,代表未来研究的机会。

指南或共识出处

  • 2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 1- Defining populations at risk, J Vet Emerg Crit Care (San Antonio).

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To expand the number of conditions and interventions explored for their associations with thrombosis in the veterinary literature and to provide the basis for prescribing recommendations.

DESIGN: A population exposure comparison outcome format was used to represent patient, exposure, comparison, and outcome. Population Exposure Comparison Outcome questions were distributed to worksheet authors who performed comprehensive searches, summarized the evidence, and created guideline recommendations that were reviewed by domain chairs. The revised guidelines then underwent the Delphi survey process to reach consensus on the final guidelines. Diseases evaluated in this iteration included heartworm disease (dogs and cats), immune-mediated hemolytic anemia (cats), protein-losing nephropathy (cats), protein-losing enteropathy (dogs and cats), sepsis (cats), hyperadrenocorticism (cats), liver disease (dogs), congenital portosystemic shunts (dogs and cats) and the following interventions: IV catheters (dogs and cats), arterial catheters (dogs and cats), vascular access ports (dogs and cats), extracorporeal circuits (dogs and cats) and transvenous pacemakers (dogs and cats).

RESULTS: Of the diseases evaluated in this iteration, a high risk for thrombosis was defined as heartworm disease or protein-losing enteropathy. Low risk for thrombosis was defined as dogs with liver disease, cats with immune-mediated hemolytic anemia, protein-losing nephropathy, sepsis, or hyperadrenocorticism.

CONCLUSIONS: Associations with thrombosis are outlined for various conditions and interventions and provide the basis for management recommendations. Numerous knowledge gaps were identified that represent opportunities for future studies.

来源:J Vet Emerg Crit Care (San Antonio),查看原文。版权归原作者所有。

参考来源

  1. deLaforcade A, Bacek L, Blais MC, et al. 2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 1- Defining populations at risk. J Vet Emerg Crit Care (San Antonio). 2022. PMID: 35499966. doi:10.1111/vec.13204

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。